Clinical Trials
Clinical and outcomes research under the direction of the Department of Dermatology is conducted both at the Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago dermatology clinics. For more information about the research or participation, please call our office at 312-695-6829.
Feinberg Clinical Trials
Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about our work via the Feinberg Office of Research Clinical Trials page.
| Trials |
|---|
DERMATOLOGY TISSUE ACQUISITION AND REPOSITORY Northwestern University’s Department of Dermatology is collecting skin, hair, nail, blood,
saliva, skin and/or buccal swabs, and mucous membrane(part of your skin which lines body
passages and cavities such as the inside of your mouth or nose), and ot… Northwestern University’s Department of Dermatology is collecting skin, hair, nail, blood,
saliva, skin and/or buccal swabs, and mucous membrane(part of your skin which lines body
passages and cavities such as the inside of your mouth or nose), and other tissue samples for use
in a biorepository. By operating this biorepository, the Department of Dermatology hopes to
develop a better understanding of skin diseases (meaning the knowledge about how cells in the
skin behave and react to medical treatments) among researchers at Northwestern University and
other approved researchers. This basic knowledge is expected to help the development of more
effective patient care and new treatment methods. -Having specimens collected as part of a standard of care procedure; -Have a skin disease which researchers want samples of in order to further understand it; or -Qualify as a healthy volunteer whose samples researchers can use as control samples for research.
STU00009443 |
A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms of Cutaneous T-Cell Lymphoma (CTCL) The main goal of … The main goal of this study is to test the efficacy and safety of topical Naloxone for itching in patients with MF. 21 years of age or older with a diagnosis of mycosis fungoides (MF) with itching present on a daily basis for more than one month and willing to fill out a diary for 7 days to provide severity of itch before enrollment.
NCT02811783 STU00203078 |
Gene Expression and Biomarker Profiling of Keloid Skin Sub-Study: A Pilot Trial of Keloid Genomic Profiling Using RNAseq Northwestern’s Department of Dermatology is performing a research study to better understand the causes of keloid scars. Keloid scars are solid tissue overgrowths that tend to d… Northwestern’s Department of Dermatology is performing a research study to better understand the causes of keloid scars. Keloid scars are solid tissue overgrowths that tend to develop after trauma to the skin. Subjects who are 18 years of age or older. Have no history of keloids or have a keloid on the earlobe or on another area of your body that either has not been treated or if treated, the treatment took place more than 6 months ago.
NCT03228693 STU00203462 |
The Gut and Skin Microbiome in Vitiligo Disease Progression Volunteers are needed for a study on the microbiome of subjects with and without vitiligo. For patients with vitiligo and without vitiligo, the study will include an initial visit, at which time swab or tape strip samples of the skin and … Volunteers are needed for a study on the microbiome of subjects with and without vitiligo. For patients with vitiligo and without vitiligo, the study will include an initial visit, at which time swab or tape strip samples of the skin and swab samples of stool will be collected. All subjects will be asked to complete questionnaires about their skin care regimen and dietary habits. Subjects with vitiligo will be required to follow up for additional specimen collection and questionnaire completion after six months and one year. |
The Impact of Pediatric Skin Disorders: The “Big” Study The purpose of this study is to understand the possible burden of skin disorders in school-age children, such as its impact on the development of anxiety, depression and relationships with friends. The study will look at the relationship … The purpose of this study is to understand the possible burden of skin disorders in school-age children, such as its impact on the development of anxiety, depression and relationships with friends. The study will look at the relationship between the burden and how severe or visible the skin problem is. Surveys can be done remotely. |
Wearable sensors and video recording for children (birth to 24 months) to monitor motor development The purpose of this study is to test flexible body-worn sensors and video technology to provide high-resolution measures of motor development in infants, starting from a very young age and continuin… The purpose of this study is to test flexible body-worn sensors and video technology to provide high-resolution measures of motor development in infants, starting from a very young age and continuing up to 2 years of age. This study will enroll up to 200 infants: 100 infants expected to have typical motor development and 100 infants at risk of atypical motor development (based on clinician diagnosis or risk factors such as prematurity, neonatal hypoxic ischemic encephalopathy, neonatal stroke, etc.). During each study visit, sensors will be placed on the legs, arms, chest, and head using soft bandage wraps or a gentle adhesive. The sensors will record the child’s movements in various postures and tasks. Their movements will also be recorded on video. These measurements will be completed at the approximate ages of 1-2 weeks, 1 months, 3 months, 6 months, 9 months, 1 year, and 2 years old. Each study visit will take about 1-2 hours. Compensation will be provided. If ever it’s too difficult to travel to one of these locations, another option is that we can come to you, and do a study visit at your home. Infant must meet the following criteria:
STU00207900 |
Wool Clothing for Atopic Dermatitis This is a clinical research study that aims to determine if there is an improvement in eczema in children when they wear superfine merino wool clothing. Participants will be randomly assigned to two groups and begin with wool garments for 6 weeks and switch to stan… This is a clinical research study that aims to determine if there is an improvement in eczema in children when they wear superfine merino wool clothing. Participants will be randomly assigned to two groups and begin with wool garments for 6 weeks and switch to standard garments for 6 weeks or begin with standard garments for 6 weeks and switch to wool garments for a further 6 weeks. Participants will attend follow-up appointments at 3, 6, 9 and 12 weeks where severity of eczema,quality of life, and any side effects will be assessed. Wool clothing and laundry detergent will be provided for the duration of the entire study. |
(xIRB) Prospective, observational, longitudinal study in pediatric patients with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not medically advisable PEDISTAD is an observational study to assess the … PEDISTAD is an observational study to assess the features of children with moderate to severe atopic dermatitis, also called eczema,whose disease is not adequately controlled with topical therapies (creams orlotions) or when those therapies are not medically advisable. Participants in this non-interventional study will be treated in the usual way for their conditions and will not undergo extra tests. The study will document how atopic dermatitis and other diseases linked to atopic dermatitis changes over time and will also investigate the influence of routine clinical practice on clinical results to understand how atopic dermatitis affects children and their caregivers in their daily lives. There is an optional, additional study that will also enroll subjects for the collection of research specimens during regularly scheduled clinic appointments for biomarker analysis. Ages <12 years old with moderate to severe atopic dermatitiswho are currently receiving systemic treatment (including phototherapy) foratopic dermatitis, or currently on topical treatment but otherwise candidatesfor systemic treatment for either lack of adequate control and/or safetyconcerns with long-term topical treatment.
STU00209263 |
An Open Label, Pilot Study Evaluating the Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia This study will test if low-dose oral minoxidil has aneffect on permanent chemotherapy-induced alopecia (defined as hair loss afterthe completion of a chemotherapy re… This study will test if low-dose oral minoxidil has aneffect on permanent chemotherapy-induced alopecia (defined as hair loss afterthe completion of a chemotherapy regimen that persists for over six months). Inthis study, you will receive the study drug; there is no placebo option. Theeffectiveness and safety of the treatment will be determined by a range of assessments,including biopsies, images, and subjective evaluation of perceived hair growth. Age 18 and above with a diagnosis of permanentchemotherapy-induced alopecia and agree to use contraception for the durationof the study.
NCT03831334 STU00206882 |
A Randomized, Single-Blind, Placebo-controlled, Self-matched pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of 0.03% RGN-137 Topical Gel in Subjects with Junctional and Dystrophic Epidermolysis Bullosa Epidermolysis bullosa(EB) is a group of genetic conditions that cause … Epidermolysis bullosa(EB) is a group of genetic conditions that cause blistering of the skin. In the Junctional EB (JEB) and Dystrophic EB (DEB) subtypes, EB wounds do not heal easily and can result in permanent and disfiguring scarring. The experimental drug in this study, a Tβ4 topical gel, is being tested in these two subtypes because of Tβ4’s wound healing characteristics. The study will compare how well 0.03% RGN-137 (Tβ4 topical gel)works and how safe it is compared to a placebo gel (which looks like the study drug but does not have any active drug ingredient) in the treatment of JEB or DEB. Males or females who are at least 4 years old with adiagnosis of Junctional EB (JEB) or Dystrophic EB (DEB).
NCT03578029 STU00209415 |
A Phase 2 Study of pembrolizumab in patients with histiocyte/dendritic cell neoplasms and biologically selected subtypes of relapsed/refractory aggressive lymphomas. (Protocol #17-448) This is a clinical research study to test the safety and effectiveness of the study drug, pembrolizumab, in treat… This is a clinical research study to test the safety and effectiveness of the study drug, pembrolizumab, in treating patients with an aggressive lymphoma or a histiocyte or dendritic cell neoplasm (tumor) that hasnot responded to or has come back after other treatments. The effectiveness and safety of the treatment will be determined by a range of assessments including biopsies, scans (or imaging tests), as well as general health and performance status. Age 18 and above with a diagnosis of a histiocyte/dendritic cell neoplasm or relapsed/refractory aggressive lymphoma. Must be willing to provide tissue from a newly obtained biopsy, have normal organ and marrow function and not a candidate for potentially curative therapy at the time of enrollment.
NCT03316573 STU00209675 |